6092 related articles for article (PubMed ID: 20609178)
1. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
2. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients.
Gejyo F; Saito A; Akizawa T; Akiba T; Sakai T; Suzuki M; Nishi S; Tsubakihara Y; Hirakata H; Bessho M;
Ther Apher Dial; 2004 Dec; 8(6):443-59. PubMed ID: 15663544
[TBL] [Abstract][Full Text] [Related]
3. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
5. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.
Lawler EV; Gagnon DR; Fink J; Seliger S; Fonda J; Do TP; Gaziano JM; Bradbury BD
Nephrol Dial Transplant; 2010 Jul; 25(7):2237-44. PubMed ID: 20083469
[TBL] [Abstract][Full Text] [Related]
6. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?
Macdougall IC
Curr Med Res Opin; 2010 Feb; 26(2):473-82. PubMed ID: 20014980
[TBL] [Abstract][Full Text] [Related]
7. ORAMA: a study to investigate EBPG impact on renal anaemia - design and baseline data.
Locatelli F; Covic A; Macdougall IC; Wiecek A;
J Nephrol; 2008; 21(4):592-603. PubMed ID: 18651551
[TBL] [Abstract][Full Text] [Related]
8. [Regarding the optimal hemoglobin target range in renal anemia].
Maurin N
Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
[TBL] [Abstract][Full Text] [Related]
9. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009.
Regidor D; McClellan WM; Kewalramani R; Sharma A; Bradbury BD
Nephrol Dial Transplant; 2011 May; 26(5):1583-91. PubMed ID: 20861195
[TBL] [Abstract][Full Text] [Related]
10. It's time to compare anemia management strategies in hemodialysis.
Coyne DW
Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
[TBL] [Abstract][Full Text] [Related]
11. [Guidelines for the treatment of anemia in chronic renal failure].
Triolo G;
G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504
[TBL] [Abstract][Full Text] [Related]
12. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
[TBL] [Abstract][Full Text] [Related]
13. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
14. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
Berns JS
Semin Dial; 2005; 18(1):22-9. PubMed ID: 15663760
[TBL] [Abstract][Full Text] [Related]
15. The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents.
Malovrh M; Hojs N; Premru V
Artif Organs; 2011 Jan; 35(1):63-8. PubMed ID: 20618233
[TBL] [Abstract][Full Text] [Related]
16. Renal anemia: comparing current Eastern and Western European management practice (ORAMA).
Wiecek A; Covic A; Locatelli F; Macdougall IC;
Ren Fail; 2008; 30(3):267-76. PubMed ID: 18350446
[TBL] [Abstract][Full Text] [Related]
17. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
Nurko S; Spirko R; Law A; Dennis VW
Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
[TBL] [Abstract][Full Text] [Related]
18. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
Dimković N
Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
[TBL] [Abstract][Full Text] [Related]
19. Optimizing anemia management in hospitalized patients with end-stage renal disease.
Heung M; Mueller BA; Segal JH
Ann Pharmacother; 2009 Feb; 43(2):276-82. PubMed ID: 19141655
[TBL] [Abstract][Full Text] [Related]
20. Anemia management and treatment response in patients on hemodialysis: the MAR study.
Portolés J; López-Gómez JM; Aljama P
J Nephrol; 2006; 19(3):352-60. PubMed ID: 16874697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]